Glimepiride: evidence-based facts, trends, and observations

References

• SchwatzPDiabetes Prevention in PracticeDresden, GermanyWCPD2010
   Google Scholar
• WildSRoglicGGreenASicreeRKingHGlobal prevalence of diabetes: estimates for the year 2000 and projections for 2030Diabetes Care20042751047105315111519
   PubMed Web of Science ®Google Scholar
• World Health OrganizationFact sheet number 312: Diabetes. Media centre fact sheet2008 Available from: http://www.who.int/mediacentre/factsheets/fs312/en/Accessed on March 29, 2012
   Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) GroupLancet199835291318378539742976
   PubMed Web of Science ®Google Scholar
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research GroupN Engl J Med1993329149779868366922
   PubMed Web of Science ®Google Scholar
• FujimotoWYBergstromRWLeonettiDLNewell-MorrisLLShumanWPWahlPWMetabolic and adipose risk factors for NIDDM and coronary disease in third-generation Japanese-American men and women with impaired glucose toleranceDiabetologia19943755245328056192
   PubMed Web of Science ®Google Scholar
• RobertsonRPPorteDJrThe glucose receptor a defective mechanism in diabetes mellitus distinct from the beta adrenergic receptorClin Invest1973524870876
   Google Scholar
• ReavenGMBanting lecture 1988. Role of insulin resistance in human diseaseDiabetes19883712159516073056758
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia20125561577159622526604
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation Clinical Guidelines Task ForceGlobal guidelines for type 2 diabetes2005 Available from: http://www.idf.org/Global_guidelineAccessed on March 29, 2012
   Google Scholar
• ShuklaUAChiEMLehrKHGlimepiride pharmacokinetics in obese versus non-obese diabetic patientsAnn Pharmacother2004381303514742789
   PubMed Web of Science ®Google Scholar
• Massi-BenedettiMGlimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experienceClin Ther200325379981612852703
   PubMed Web of Science ®Google Scholar
• KorytkowskiMThomasAReidLTedescoMBGoodingWEGerichJGlimepiride improves both first and second phases of insulin secretion in type 2 diabetesDiabetes Care20022591607161112196435
   PubMed Web of Science ®Google Scholar
• CampbellRKGlimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitusAnn Pharmacother19983210104410529793597
   PubMed Web of Science ®Google Scholar
• RosenkranzBPharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patientsHorm Metab Res19962894344398911979
   PubMed Web of Science ®Google Scholar
• GoldbergRBHolveySMSchneiderJThe Glimepiride Protocol #201 Study Group. A dose response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agentsDiabetes Care199619847856
   Web of Science ®Google Scholar
• Wernicke-PantenKHauptEPfeifferCEarly onset of pharmacodynamic effects of glimepiride in type II diabetic patients [abstract]Diabetologia199437Suppl 1A163
   Google Scholar
• Massi-BenedettiMHerzMPfeifferCThe effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamideHorm Metab Res1996284514558911982
   PubMed Web of Science ®Google Scholar
• RosskampRHerzMEffect of the time of ingestion of the sulfonylurea glimepiride on the daily blood glucose profile in NIDDM patients [abstract]15th Int Diab Fed Congr1994416
   Google Scholar
• OverkampDVolkAMaerkerEAcute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetesDiabetes Care200225112065207312401758
   PubMed Web of Science ®Google Scholar
• MüllerGThe molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug AmarylMol Med200061190793311147570
   PubMed Web of Science ®Google Scholar
• MüllerGWiedSWetekamEMCreceliusAUnkelbachAPünterJStimulation of glucose utilization in 3T3 adipocytes and rat diaphragm in vitro by the sulphonylureas, glimepiride and glibenclamide, is correlated with modulations of the cAMP regulatory cascadeBiochem Pharmacol19943048985996
   Web of Science ®Google Scholar
• VéghAPappJGHaemodynamic and other effects of sulphonylurea drugs on the heartDiabetes Res Clin Pract1996Suppl 31S43538864640
   PubMedGoogle Scholar
• MüllerGWiedSStraubJJungCCoordinated regulation of esterification and lipolysis by palmitate, H2O2 and the anti-diabetic sulfonylurea drug, glimepiride, in rat adipocytesEur J Pharmacol20085971–361818789917
   PubMed Web of Science ®Google Scholar
• BriscoeVJGriffithMLDavisSNThe role of glimepiride in the treatment of type 2 diabetes mellitusExpert Opin Drug Metab Toxicol20106222523520055691
   PubMed Web of Science ®Google Scholar
• MocanuMMMaddockHLBaxterGFLawrenceCLStandenNBYellonDMGlimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxideCirculation2001103253111311611425777
   PubMed Web of Science ®Google Scholar
• LangtryHDBalfourJAGlimepiride: a review of its use in the management of type 2 diabetes mellitusDrugs19985545635849561345
   PubMed Web of Science ®Google Scholar
• GeisenKVeghAKrauseEPappJGCardiovascular effects of conventional sulfonylureas and glimepirideHorm Metab Res1996284965078911987
   PubMed Web of Science ®Google Scholar
• GoldbergRBHolveySMSchneiderJA dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study GroupDiabetes Care19961988498568842603
   PubMed Web of Science ®Google Scholar
• SonnenbergGEGargDCWeidlerDJShort-term comparison of once - versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitusAnn Pharmacother1997316716769184703
   PubMed Web of Science ®Google Scholar
• RosenstockJSamolsEMuchmoreDBSchneiderJGlimepiride, a new once-daily sulphonylurea. a double-blind placebo-controlled study of NIDDM patients. Glimepiride Study GroupDiabetes Care199619119411998908379
   PubMed Web of Science ®Google Scholar
• SchadeDSJovanovicLSchneiderJA placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessfulJ Clin Pharmacol19983876366419702849
   PubMed Web of Science ®Google Scholar
• CharpentierGFleuryFKabirMVaurLHalimiSImproved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patientsDiabet Med2001181082883411678974
   PubMed Web of Science ®Google Scholar
• McCluskeyDTougerMSMelisRSchleusenerDSResults of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapyClin Ther200426111783179015639690
   PubMed Web of Science ®Google Scholar
• UmpierrezGIssaMVlajnicAGlimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trialCurr Med Res Opin200622475175916684436
   PubMed Web of Science ®Google Scholar
• DillsDGSchneiderJClinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research GroupHorm Metab Res19962894264298911977
   PubMed Web of Science ®Google Scholar
• DraegerKEWernicke-PantenKLompHJSchulerERosskampRLong-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamideHorm Metab Res19962894194258911976
   PubMed Web of Science ®Google Scholar
• SchernthanerGGrimaldiADi-MarioUGUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patientsEur J Clin Invest20043453554215305887
   PubMed Web of Science ®Google Scholar
• RahmanIUMalikSABashirMKhanRUIdreesMMonotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitusBrit J Diab Vas Dis2011113137140
   Google Scholar
• GarberAJBenefits of combination therapy of insulin and oral hypoglycemic agentsArch Intern Med2003163151781178212912710
   PubMedGoogle Scholar
• RiddleMCCombined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routineHorm Metab Res1996284304338911978
   PubMed Web of Science ®Google Scholar
• RiddleMCSchneiderJBeginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination GroupDiabetes Care1998217105210579653594
   PubMed Web of Science ®Google Scholar
• FritscheASchweitzerMAHäringHUGlimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trialAnn Intern Med20031381295295912809451
   PubMed Web of Science ®Google Scholar
• SchneiderJAn overview of the safety and tolerance of glimepirideHorm Metab Res1996284134188911975
   PubMed Web of Science ®Google Scholar
• HolsteinAPlaschkeAEgbertsEHLower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamideDiabetes Metab Res Rev200117646747311757083
   PubMed Web of Science ®Google Scholar
• MüllerGThe molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug AmarylMol Med200061190793311147570
   PubMed Web of Science ®Google Scholar
• HeineRJRole of sulfonylureas in non-insulin-dependent diabetes mellitus: part II – ‘the cons’Horm Metab Res1996285225268911991
   PubMed Web of Science ®Google Scholar
• TrembleJMDonaldsonDIs continued weight gain inevitable in type 2 diabetes mellitus?J R Soc Promot Health199911923523910673844
   PubMedGoogle Scholar
• ScholzGSchneiderKKnirschWBeckerGEfficacy and tolerability of glimepiride in daily practice: a non-interventional observational cohort studyClin Drug Invest2001219597604
   Web of Science ®Google Scholar
• WeitgasserRLechleitnerMLugerAKlinglerAEffects of glimepiride on HbA1c and body weight in type 2 diabetes: results of a 1.5-year follow-up studyDiabetes Res Clin Pract200361131912849919
   PubMed Web of Science ®Google Scholar
• MartinSKolbHBeuthJvan LeendertRSchneiderBScherbaumWAChange in patients’ body weight after 12 months of treatment with glimepiride or glibenclamide in type 2 diabetes: a multicentre retrospective cohort studyDiabetologia200346121611161714600814
   PubMed Web of Science ®Google Scholar
• DraegerKWernicke-PantenKLompHJSchulerERosskampRLong-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamideHorm Metab Res1996284194258911976
   PubMed Web of Science ®Google Scholar
• MüllerGHartzDPünterJOkonomopulosRKramerWDifferential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristicsBiochim Biophys Acta199411912672778172912
   PubMed Web of Science ®Google Scholar
• MüllerGSatohYGeisenKExtrapancreatic effects of sulfonylureas – a comparison between glimepiride and conventional sulfonylureasDiabetes Res Clin Pract1995Suppl 28S1151378529504
   PubMed Web of Science ®Google Scholar
• Hoechst-Roussel Pharmaceuticals, Inc Amaryl (glimepiride) prescribing informationSomerville, NJHoechst-Roussel Pharmaceuticals, Inc1995
   Google Scholar
• HydrieMZIGulAHakeemRAhmadaniMYBasitAGlimepiride study on type-2 diabetic subjectsPak J Med Sci200622132135
   Google Scholar
• BugosCAustinMAthertonTViereckCLong-term treatment of type 2 diabetes mellitus with glimepiride is weight neutral: a meta-analysisDiabetes Res Clin Pract200050Suppl 1S4711080562
   PubMed Web of Science ®Google Scholar
• RosenstockJFitchetMVildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetesInt J Clin Pract Suppl2008159152318269437
   PubMedGoogle Scholar
• GarberAJFoleyJEBanerjiMAEffects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylureaDiabetes Obes Metab200810111047105618284434
   PubMed Web of Science ®Google Scholar
• FonsecaVBaronMShaoQDejagerSSustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitusHorm Metab Res20084042743018401832
   PubMed Web of Science ®Google Scholar
• MatthewsDRDejagerSAhrenBVildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year studyDiabetes Obes Metab20101278078920649630
   PubMed Web of Science ®Google Scholar
• DejagerSRazacSFoleyJESchweizerAVildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose studyHorm Metab Res20073921822317373638
   PubMed Web of Science ®Google Scholar
• JeonHJOhTKComparison of Vildagliptin-metformin and glimepiridemetformin treatments in type 2 diabetic patientsDiabetes Metab J20113552953522111045
   PubMedGoogle Scholar